A new study reveals that a large number of scientists are “spinning” the results of clinical trials for new breast cancer drugs.

The researchers analyzed more than 160 phase III clinical trials for breast cancer treatments during 1995 and 2011 and also found that over two-thirds of the trials were biased as they under-reported the adverse effects of the drugs.
“Better and more accurate reporting is urgently needed. Journal editors and reviewers, who give their expertise on the topic, are very important in ensuring this happens. However, readers also need to critically appraise reports in order to detect potential bias. We believe guidelines are necessary to improve the reporting of both efficacy and toxicity”, lead researcher Professor Ian Tannock said.
Source-Medindia
MEDINDIA




Email










